Should MRD negativity post remission impact treatment decisions in ELN-intermediate risk AML?

MRD-guided therapy in patients with intermediate-risk AML compared to unguided cohort using PSMПодробнее

Post Remission Decisions in AMLПодробнее

Post-remission Strategies in AMLПодробнее

MRD negativity predicts improved survival in AMLПодробнее

Induction and post-remission treatment strategies for patients with NPM1/DNMT3A co-mutated AMLПодробнее

Determining the most suitable consolidation therapies for AML by defining patient risk groupПодробнее

Treatment of intermediate-risk AML with gemtuzumab ozogamicinПодробнее

Implementing MRD in clinical practice for patients with intermediate-risk AMLПодробнее

When should patients with intermediate-risk AML be indicated for alloSCT?Подробнее

MRD Monitoring in Acute Myeloid LeukemiaПодробнее

How I Think and Treat in the New Age of AML CareПодробнее

Understanding Risk in AML: How Molecular Testing Affects Treatment OptionsПодробнее

AML Treatment Decisions | Understanding Factors That Impact Your OptionsПодробнее

Managing Life With AML | What You Should Know About Care and TreatmentПодробнее

Best of ASH22 AMLПодробнее

New Findings and Improved Outcomes in the Treatment of AMLПодробнее

The impact of cytogenetic-risk stratification on AML outcomesПодробнее

The impact of cytogenetics on treatment decisions in AMLПодробнее